Courtney Sherman, MD
Orthopaedic Surgery · Jacksonville, FLNPI 1427179142
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Davol Inc. at 31.2% of the total. Reporting peaked in 2023 at $179 and has fallen 81.1% since, to $34 in 2025. That places this record below the midpoint for orthopaedic surgery clinicians in FL, where the typical reported total is $5,564.
Across 10 payments — averaging $60.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$190
- Onkos Surgical, Inc.$186
- Stryker$135
- Bone Support Inc.$63
- Gilead$23
- Takeda Pharmaceuticals U.S.A., Inc.$12
Across 4 payments — averaging $1330.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Omnilife Science, Inc$4K
- Corin USA$2K
What the payments were for
- Food & beverage$608100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 2 | $190 |
| Onkos Surgical, Inc. | 3 | $186 |
| Stryker | 2 | $135 |
| Bone Support Inc. | 1 | $63 |
| Gilead | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$608 in reported general payments places this provider in the 20th percentile of 1,263 orthopaedic surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Monohydrate | 15 | $987 |
| Gabapentin | 17 | $146 |
| Meloxicam | 15 | $62 |
| Amoxicillin | 25 | $44 |
| Tramadol Hcl | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Jacksonville
- Bryan SpringerJacksonville$6.3M
- Jorge AcevedoJacksonville$3.3M
- Rahul DeshmukhJacksonville$769K
- Andrew CooperClearwater$102M
- Richard HynesMelbourne$34.8M
- Mark FrankleTemple Terrace$31M
- Roy SandersTemple Terrace$19.6M
- George HaidukewychOrlando$10M
- Robert SantrockFernandina Beach$7.3M
- Martin RocheFt. Lauderdale$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.